Bente L.
- Country
- Denmark
- Department
- Medicinsk Endokrinologisk Afdeling (MEA)
Research Overview
- Treatment with zoledronate subsequent to denosumab in osteoporosis 2
- Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study of AGA2115, a Humanised IgG4 Bispecific Anti‑Sclerostin/DKK1 Antibody, in Adults with Osteogenesis Imperfecta
- Evaluation of Denosumab on Insulin Sensitivity and Muscle Strength in Patients with Diabetes Mellitus and Postmenopausal Osteoporosis
Data & Insights
Has run more than one trial at 4 of 21 partner sites.
Specializations
Metabolic Bone Disorders
The investigator specializes in various forms of metabolic bone disorders, with particular emphasis on osteoporosis and its manifestations in different patient populations.
- Postmenopausal Osteoporosis Management
- Bone Mineral Density Assessment
- Osteogenesis Imperfecta Treatment
Their work encompasses comprehensive evaluation and treatment of bone mass conditions using various therapeutic approaches.
Therapeutic Innovation
The investigator focuses on advancing novel treatment strategies for bone disorders, including the evaluation of emerging therapeutic agents and combination therapies.
- Sequential Therapy Approaches
- Bone Formation Agents
- Antiresorptive Treatments
Their research explores optimal treatment sequences and therapeutic transitions in bone disorders.
Metabolic Health
The investigator examines the intersection between bone metabolism and other systemic conditions, particularly focusing on diabetes mellitus and muscle health.
- Insulin Sensitivity
- Muscle Strength Assessment
- Metabolic Bone Markers
Their work investigates the complex relationships between bone health and metabolic functions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.